Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120362) titled 'To evaluate the safety and efficacy of Apololitowereili Monoclonal Antibody combined with FLOT regimen in patients with locally advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma' on March 12.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Fuzhou University Affiliated Provincial Hospital
Condition:
Locally advanced HER2-negative adenocarcinoma of the stomach or gastroesophageal junction
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-03-15
Target Sample Size: experimental group:29;
Countries of Recruitment:
China
To kno...